Introduction
Periodontal disease (PD) is a chronic inflammatory disease where resident cells and preformed mediators induce leukocyte infiltration and progressive destruction of the tooth-supporting tissues as a result of interaction between bacterial products, cell populations, and mediators in disease-susceptible individuals. [1] This is a complex disease with multifactorial etiology and influenced by genetic and environmental risk factors. Rheumatoid arthritis (RA) is a systemic, inflammatory disease that is chronic and progressive, which affects primarily the synovial membrane of the joints and may lead to the destruction of bone and cartilage. [2] Global records indicate that the occurrence rate of this disease in the adult population is about 1% in all ethnic groups, predominantly in females where it
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For reprints contact: reprints@medknow.com is two to three times more prevalent when compared to males. [3] RA and periodontitis share some common pathogenic features; both are chronic inflammatory diseases with immune-regulatory imbalance, genetic and environmental influences leading to the destruction of conjunctive, and hard tissues. [4] A previous study has reported that the frequency of RA is significantly higher in patients with periodontal disease than in patients without periodontitis (3.95% vs. 0.66%). [5] In addition, other similar studies have reported a higher incidence of missing teeth, dental plaque, greater periodontal pocket depth (PD), or worse clinical attachment levels (CALs) in patients with RA. [6] Growing evidence suggests that pathogens such as Porphyromonas gingivalis which are associated with periodontal disease could play a role in RA propagation. P. gingivalis is the only known pathogen expressing peptidyl-arginine deiminase which is similar to its human counterpart. This enzyme catalyzes the citrullination of arginine-containing peptides and citrullinated antigens that are thought to drive adaptive immune responses which are exclusive to RA. [7] Concentrations of circulating antibody to P. gingivalis have been revealed to be associated with the expression of anti-citrullinated peptide antibody (ACPA). [7] Curcumin has been consumed as a dietary supplement for centuries and is considered pharmacologically safe. [8] In ayurvedic medicine, it has been widely used for its antioxidant, anti-inflammatory, analgesic, antiseptic, and antimalarial properties. [8] Essential oils are volatile aroma compounds derived from the plants and are known for their anti-inflammatory, antimicrobial, and antioxidant properties.
Research suggests that oxygenated terpenoids found in the essential oils diffuse within the bacterial cell membrane, irreversibly damaging it, and causing cell death. [9] Although previous studies have shown that periodontal treatment might induce a significant decrease in erythrocyte sedimentation rate (ESR) or disease activity scores in 28 joints in RA patients, [10, 11] none as of date has been conducted to assess the effect of mouthwash containing essential oils and curcumin (MEC) as an adjunct to periodontal therapy among the patients with RA. Hence, a randomized controlled trial was conducted with the aim to assess RA disease activity after non-surgical periodontal therapy with MEC and chlorhexidine as adjunctive mouthwashes.
Materials and Methods

Subjects and study design
A triple-blinded randomized controlled trial with concurrent parallel design was carried out among 45 females randomly recruited from August 2016 to January 2017 from a private rheumatology clinic in Guntur city, Andhra Pradesh, India. All patients included in the trial were dentate with minimum 20 teeth and were diagnosed with both RA and moderate chronic periodontitis (CP). RA was diagnosed according to the revised criteria of the American College of Rheumatology, 2010. [12] All selected patients had a joint involvement score of three (4-10 small joints, with or without involvement of large joints) and were under similar medication for RA for the past 1 month (Non-Steroidal anti-inflammatory drug included etodolac and disease-modifying antirheumatic drugs included methotrexate at a dosage determined by the treating rheumatologist based on patient's needs). The diagnostic criteria for moderate CP were the presence of at least two interproximal sites not on the same tooth with probing depth of ≥5 to <7 mm or clinical attachment loss of 3-4 mm or presence of 16%-30% radiographic bone loss with bleeding on probing. [13] Patients with a history of previous antibiotic therapy or periodontal therapy in the past 6 months, systemic diseases other than RA, hypersensitivity to mouthwashes, pregnant women, and tobacco users were excluded from the study. Patients were instructed to continue their regular medications for RA and not to undergo any new treatment for RA during the trial period.
The present study was conducted by the guidelines for good clinical practice and with the Helsinki Declaration of 1975, as revised in 2000. The protocol was approved by the Institutional Ethical Committee of Meenakshi Ammal dental College and Hospital, Chennai, India (MADC/IEC/002/2016), and all the patients provided written informed consent to participate in this study. This trial has been registered in the Clinical Trial Registry of India (CTRI/2017/01/007713). The description of this clinical trial follows the recommendations made by CONSORT in 2010.
No external funding was received for this study.
Sample size estimation
This pilot study was conducted among 15 patients (five patients in each group) who satisfied the inclusion criteria to assess the feasibility and sample size for the main study. Sample size estimation was made taking into account the mean difference in serum ACPA levels (since ACPA was considered as a major outcome measure of this study). Using a sampling software, (G power version 3.1.9.2, Heinrich-Heine-Universitat-Dusseldorf, Germany) minimum sample size was calculated to be 13 patients in each group (power 90% and α error at 5%). It was increased to 15 patients in each group based on anticipated dropout rate of 10% as estimated from the previous hospital records. A single examiner performed the clinical examination who was calibrated before the pilot study, and the intraexaminer reliability was assessed (Cronbach's α = 0.87).
Randomization and blinding
Information on intervention allocation was placed in opaque envelopes and patients were asked to choose one envelope randomly. An independent investigator noted the group allocation of each patient, to which the chief investigator was blinded. Intervention allocation was revealed only after the data analysis was completed. The selected patients were randomly assigned into three groups, each group consisting of 15 patients as follows: Group A: scaling and root planning (SRP) with 0.2% chlorhexidine mouthwash as an adjunct, Group B: SRP with MEC as an adjunct, and Group C: SRP alone. The interventions were masked by dispensing them into identical cleaned, opaque amber plastic bottles with appropriate labeling done to avoid patient bias. The experimental mouthwash used in this study is commercially available and its constituents include
and tea tree oil (0.45%v/v).
Clinical examination
The plaque index proposed by Silness and Loe in 1967 was used for the assessment of plaque accumulation. [14] For measuring PD, William's periodontal probe was inserted between the tooth and the gingiva, and the distance from the gingival margin to the base of the pocket was noted against the measuring lines on the probe. The level of attachment was measured as the distance between the base of the pocket and a fixed point on the crown such as the cement-enamel junction. A tooth was probed in six sites, the mesiobuccal, midbuccal, distobuccal, and the corresponding sites on the lingual surface. Orthopantomograms of the patients were obtained and read by a periodontist for the confirmation of the diagnosis as moderate CP.
Periodontal therapy
Patients in all three groups received nonsurgical periodontal therapy, which consisted of full mouth SRP using ultrasonic scaler in 1-2 sessions (with a time interval of 24 h between each session) by a single periodontist. Patients in Group A and B were advised to use 10 ml of respective mouthwash undiluted for 1 min twice a day 30 min after brushing (as per manufacturer instructions). All the patients received oral hygiene instructions along with an oral hygiene kit containing a soft-bristled toothbrush and fluoridated toothpaste during the study.
Hematological examination
Venous blood samples were obtained by venepuncture under aseptic conditions from the antecubital fossa by a phlebotomist. After placement of a tourniquet, 5 ml of blood were collected using a 5-ml syringe from the median cubital vein in the antecubital region. The fasting blood samples were collected from the study patients between 6:30 and 9:30 AM, and were immediately transferred into K 3 EDTA vacutainers. The vacutainers were then labeled and sent to the hematology laboratory of the affiliated hospital's pathology department, where a pathologist blinded to the clinical data performed the hematological investigations. The ESR (Wintrobe's method), C-reactive protein (CRP) (laser nephelometry), rheumatoid factor (RF) (enzyme-linked immunosorbent assay [ELISA]), and anticitrullinated protein antibody (ACPA) (ELISA) were measured.
Both hematological parameters of RA and clinical parameters of moderate CP were assessed at baseline and 6 weeks after intervention.
Statistical analysis
Statistical analysis was carried out using the statistical software SPSS version 16 (IBM. corp. Chicago., USA). Intergroup comparison of demographic data about the cultural identity, area of residence, and socioeconomic status was carried out using Pearson's Chi-square test. Quantitative data comprising clinical and hematological parameters were tested for normality using Shapiro-Wilks test and were found to be parametric in distribution. (P > 0.05).
Comparison of mean differences about clinical and hematological parameters between three treatment groups at individual time frames was carried out using one-way ANOVA and subsequent pair-wise comparison were done using Tukey's post hoc test. Intragroup mean differences for the above-mentioned parameters between baseline and 6 weeks were carried out using the paired sample t-test.
Percentage reduction in the values for both clinical and hematological parameters was estimated and compared between the three treatment groups using one-way ANOVA test followed by Tukey's post hoc test. A value of P < 0.05 was considered as statistically significant.
Results
Among the 45 patients who were initially enrolled in the study, 44 participated throughout the entire span of the study. One patient in Group C dropped out of the study due to a knee fracture [ Figure 1 ]. No patients were excluded due to lack of compliance with or intolerance to either treatment regimen. Demographic distribution of patients in the three treatment groups has been revealed in Table 1 .
Inflammatory biomarkers
Baseline characteristics did not differ significantly between the three groups. A significant reduction in ESR, RF, CRP, and ACPA was observed in all treatment groups individually between the two-time points (baseline vs. 6 weeks) (P < 0.001) [ Table 2 ].
When the percentage mean reductions of the above-mentioned parameters were observed, patients in Group B showed the highest percentage mean reduction of inflammatory biomarkers of RA followed by Group A and Group C. A significant difference in percentage mean 
Clinical parameters
A significant reduction in plaque index scores, PD, and CAL was observed in all treatment groups individually between two time frames (baseline vs. 6 weeks). (P = 0.000) [ Table 2 ] When the percentage mean reductions (from baseline to six weeks) of the above-mentioned parameters were observed, patients in Group B showed the highest percentage mean reduction of plaque index scores followed by Group A and Group C. A significant difference in percentage mean reduction of plaque index scores was observed between Group A and Group C and Group B and Group C, respectively (P = 0.001). However, the difference in percentage mean reduction of plaque index scores between Group A and Group B was not statistically significant (P = 0.243) [ Table 3 ]. The highest percentage mean reduction of PD and CAL was observed in Group A followed by Group B and Group C. The difference was observed in the percentage mean reduction of PD and CAL between the three treatment groups was statistically significant (P = 0.001) [ Table 4 ].
Discussion
This is the first reported study to evaluate the effect of MEC when used as an adjunct to nonsurgical periodontal therapy on the disease activity of both RA and moderate CP. Heritable changes in gene expression that does not involve changes to the underlying DNA sequence are studied through epigenetics. Epigenetic modifications include chemical alterations of DNA and associated proteins leading to the remodeling of the chromatin and gene malfunctions which may be linked to both RA and periodontitis. These epigenetic alterations have been linked to the X chromosome which may, partly, explain the predominant female prevalence of RA. [15] Hence, in the 132.57±8.35 0.000* *P highly significant (P<0.001). CAL=Clinical attachment level, RF=Rheumatoid factor, ESR=Erythrocyte sedimentation rate, CRP=C-reactive protein, ACPA=Anticitrullinated protein antibody, Group A=SRP + chlorhexidine, Group B=SRP + MEC, Group C=SRP alone, SRP=Scaling and root planning, MEC=Mouthwash containing essential oils and curcumin, SD=Standard deviation reduction of all the RA parameters was observed between Group A and Group B; between Group B and Group C; and between Group A and Group C (P = 0.001) [ Table 3 ]. target-specific periopathogens. Certain periopathogens including P. gingivalis may invade the gingival tissues and are thus spared from mechanical debridement providing the source for recolonization of periodontal pockets. [16] Hence, chemical plaque control is advocated as an adjuvant treatment for such tissue invading periopathogens.
Inflammatory biomarkers
The current clinical trial showed that, after nonsurgical periodontal treatment, there was a reduction in inflammatory markers in RA patients with moderate CP, corroborating the impact of the periodontal condition on RA, and a finding similar to previous studies. [10, 11] ESR and CRP are the systemic inflammatory markers that can be used to determine the degree of activity of RA at a given point in time. In this regard, a significant decrease in ESR and CRP was observed following periodontal treatment. Two studies showed a significant decrease in ESR values in the RA patients following periodontal treatment. [10, 11] In this study, a statistically significant decrease in CRP levels was detected 6 weeks after nonsurgical periodontal therapy. This finding on the reduction in CRP values was by the results of a previous study, a reduction was observed in CRP levels 4 weeks after nonsurgical periodontal therapy. [17] Data have shown that ACPA in addition to the RF predate the onset of RA with ACPA levels having the highest predictive value. [18] The results of the present study showed a significant reduction in ACPA levels in all the three groups. Thus, the improvement in RA condition after periodontal therapy might be attributed to a reduction in these markers.
Another possible explanation is that elimination of periodontal pathogens by periodontal therapy might reduce exposure of the joints structures to bacteria and their toxins and subsequently lead to improved RA conditions.
Clinical parameters
The results of the current trial showed a significant improvement in all clinical parameters of the periodontitis in all groups. This can be explained by the fact that thorough SRP has an impact on the clinical findings, irrespective of the adjunctive treatment procedures. These results pertaining to the clinical parameters of periodontitis are consistent with the previous study. [19] In the present study, the intergroup comparison of periodontal PD and CALs showed a better result for chlorhexidine group compared to its study counterparts, which were by the previous study. [20] The reduction observed in mean plaque scores observed in our study were consistent with the previous study, where turmeric was prescribed along with routine oral hygiene measures, however, not in RA patients. [21] The probable explanation for the above observation lies in the antiplaque effect of curcumin as this was an ingredient of the mouthwash used in both studies. In a previous study, plaque reduction and gingivitis reduction ---*Highly significant (P<0.001). Group A=SRP + chlorhexidine, Group B=SRP + MEC, Group C=SRP alone CAL=Clinical attachment level, SD=Standard deviation, SRP=Scaling and root planning, MEC=Mouthwash containing essential oils and curcumin current trial the eligibility was restricted to female patients with RA.
Over many years, the fundamental treatment of periodontitis has been consistent with the removal of plaque/biofilm and calculus through SRP. Nevertheless, it has been noted that all the patients might not respond to mechanical debridement alone as this treatment aims at removing the whole dental plaque rather than were observed when a mouthwash containing essential oils was used twice daily for 6 weeks. [17] Guntur city has only two hospitals exclusively for treating RA, and one of it was selected for this study. The patients were selected randomly from this hospital, and hence, the study results can be generalized to a wider population. Shorter duration follow-up and inability to conduct microbiological analysis of plaque samples could be listed as few limitations of our study.
Conclusion
In summary, we have provided quality evidence to suggest that the commercially available mouthwash containing essential oils with curcumin when used as an adjunct to SRP showed a significant reduction in the disease activity of RA and CP among the study patients compared to other two treatments. The findings of this study may have influence on clinical practice and potentially contribute to further development of new research directions for both dentists and rheumatologists.
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